Bet there was a drink or two when drafting this.. pretty great.
Complete Response Patient Case StudyThe patient with a confirmed complete response (CR) was diagnosed with triple-negative breast carcinoma(TNBC) in 2019 and has failed multiple lines of therapy including a CDK 4/6 inhibitor for ER+/PR+ metastasisDuring the immuno-oncology (IO)-chemotherapy treatment of efti and paclitaxel, this patient achieved apartial response (PR) that subsequently turned into a CR. This patient's ongoing CR has been maintained sincestopping paclitaxel and being treated with efti monotherap
Just now need n=300sample. Surely there must be some big pharma getting the fomo shakes.
Bet there was a drink or two when drafting this.. pretty...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $534.9M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3373 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 2712 | 1 |
View Market Depth
| Last trade - 16.16pm 03/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
Day chart unavailable